Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. | Another biotech is squeezing ...
KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...
Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results